School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Tasmania, Australia.
Launceston Clinical School, Tasmanian School of Medicine, University of Tasmania, Launceston, Tasmania, Australia.
Eur J Clin Invest. 2021 Jun;51(6):e13489. doi: 10.1111/eci.13489. Epub 2021 Jan 22.
To examine the change in stroke risk over time and determine the proportion of patients with atrial fibrillation (AF) who were initiated on an oral anticoagulant (OAC) as their stroke risk increased from low/moderate to high, using the Australian general practice data set, MedicineInsight.
A total of 2296 patients diagnosed with AF between 1 January 2007 and 31 December 2008, aged 18 years or older and not initiated on an OAC before 2009, were included. We assessed the change in stroke risk and the proportion of patients who had a recorded prescription of an OAC, each year from 1 January 2009 to 31 December 2018.
At baseline, 23.9%, 22.9% and 53.2% were categorised as being at low (score = 0), moderate (score = 1) and high stroke risk (score ≥ 2), respectively, using the sexless CHA DS -VASc (CHA DS -VA) score. Overall, the CHA DS -VA score increased by a mean of 1.34 (95% confidence interval, 1.29-1.39) points over the study period. Nearly two-thirds of patients (65%, 412/632) whose stroke risk changed from baseline low/moderate to high were subsequently prescribed an OAC. The median (interquartile range) lag time from becoming high stroke risk to having OAC initiation was 2 (5) years.
Nearly one-third of patients reclassified as being at high risk of stroke during the study period were not prescribed OAC therapy. Furthermore, the delay in OAC initiation following classification as being at high risk was a median of 2 years, suggesting that more frequent stroke reassessment is needed.
利用澳大利亚全科医疗数据库 MedicineInsight 研究随时间推移卒中风险的变化,并确定随着卒中风险由低/中危升高至高危,因卒中风险升高而开始使用口服抗凝剂(OAC)的患者比例。
共纳入 2007 年 1 月 1 日至 2008 年 12 月 31 日期间诊断为房颤且年龄≥18 岁且 2009 年前未开始使用 OAC 的 2296 例患者。评估 2009 年 1 月 1 日至 2018 年 12 月 31 日期间每年的卒中风险变化和开始 OAC 治疗的患者比例。
根据无性别 CHA2DS2-VASc(CHA2DS2-VASc)评分,基线时分别有 23.9%、22.9%和 53.2%的患者被归类为低危(评分=0)、中危(评分=1)和高危(评分≥2)。总体而言,研究期间 CHA2DS2-VASc 评分平均增加 1.34 分(95%置信区间,1.29-1.39)。近三分之二(65%,412/632)的患者从基线时的低/中危变为高危后被开具了 OAC。从中危变为高危后开始使用 OAC 的中位(四分位间距)时间延迟为 2(5)年。
研究期间近三分之一重新分类为高危卒中的患者未接受 OAC 治疗。此外,高危分类后开始 OAC 治疗的延迟中位数为 2 年,表明需要更频繁地进行卒中再评估。